ArticlePharmacology research & perspectives2026
The Novel TRPV1 Agonist ST-6631 Improves Swallowing Function in Rat Models of Stroke-Related Dysphagia and Demonstrates Pharmaceutical Advantage Over Capsaicin, by Exhibiting Minimal Pungent and Irritant Properties.
Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysphagia, often associated with neurological disorders such as stroke, not only damages patients' quality of life, like the joy of engaging with meals, but also adversely affects mortality among patients by increasing risks of getting aspiration pneumonia. There are currently no approved drug-based treatments, leaving dysphagic symptom management as unmet clinical needs. Nevertheless, transient receptor potential vanilloid 1 (TRPV1) channel has gained clinical interest to enhance the sensitivity of sensory nerves that facilitate swallowing reflexes in the pharynx. Here, a novel TRPV1 agonist and antedrug candidate ST-6631 has been introduced, with its therapeutic efficacy comparable to the natural ligand capsaicin, in rats operated with permanent bilateral carotid artery occlusion (BCAO), the animal model of stroke-related dysphagia. The ST-6631 antedrug properties have shown rapid metabolism by the hepatic S9 enzymatic fractions, and also shown extremely limited systemic bioavailability in blood circulation after the oral administration in vivo to rats. Furthermore, ST-6631 has been described to possess minimal pungency and irritancy in behavioral sensory assessments in awake rats. ST-6631 has been revealed to provide only a modest form of depolarization in rat sensory dorsal root ganglion (DRG) neurons. In addition, ST-6631 moderately activates the TRPV1 current, characterized by slower but long-lasting waveforms, in the channel-expressing Chinese hamster ovary (CHO) cells. Hence, the present study collectively highlights the pharmaceutically desired product profile of ST-6631, achieving TRPV1 agonism with minimal adverse effects, in clear contrast to the noxious reference ligand, capsaicin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.